Separately, Zacks Investment Research raised shares of COLLPLANT HOLDI/S from a hold rating to a buy rating and set a $5.25 price target for the company in a research report on Tuesday, July 2nd.
NASDAQ CLGN opened at $3.35 on Tuesday. The company has a fifty day simple moving average of $4.21. COLLPLANT HOLDI/S has a 12-month low of $3.13 and a 12-month high of $8.73. The company has a current ratio of 1.66, a quick ratio of 1.41 and a debt-to-equity ratio of 0.95. The firm has a market cap of $13.30 million, a P/E ratio of -6.09 and a beta of 1.34.
About COLLPLANT HOLDI/S
CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, dermal fillers for aesthetics, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe.
Read More: Blue-Chip Stocks
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for COLLPLANT HOLDI/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COLLPLANT HOLDI/S and related companies with MarketBeat.com's FREE daily email newsletter.